| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
To determine the effect of infliximab on microRNA (miRNA) expression in peripheral blood mononuclear cells of Behcet's disease patients before and after initiation of infliximab treatment, we analyzed miRNA expression profiles in 4 patients at baseline and at 22 weeks after initiation of infliximab. Anti-TNF-α antibody therapy reduced the frequency of ocular attacks in 3 of 4 patients during 2 years of follow-up, while one patient continued to have inflammatory relapses during that time. Several miRNAs were increased or decreased in each patient. Although the expression of miRNA-144 was decreased in all 3 patients with no relapses, its expression was increased in the one patient who continued to have relapses. MiRNA-144 may represent a new biomarker for monitorings response to infliximab in the treatment of Behcet’s disease with refractory uveoretinitis.
|
